1380109-83-0Relevant academic research and scientific papers
Novel monobactams utilizing a siderophore uptake mechanism for the treatment of gram-negative infections
Mitton-Fry, Mark J.,Arcari, Joel T.,Brown, Matthew F.,Casavant, Jeffrey M.,Flanagan, Mark E.,Gerstenberger, Brian S.,Harris, Thomas M.,Hoang, Thuy,Lall, Manjinder S.,Li, Chao,Noe, Mark C.,Plummer, Mark S.,Risley, Hud,Schuff, Brandon P.,Starr, Jeremy T.,Sun, Jianmin,Young, Jennifer A.,Shanmugasundaram, Veerabahu,Finegan, Steven M.,George, David M.,Huband, Michael D.,Irvine, Rebecca,Megan Lemmon, M.,McCurdy, Sandra P.,Mueller, John P.,Mullins, Lisa,Penzien, Joseph,Gao, Hongying,Hardink, Joel R.,Lin, Jian,Niosi, Mark,Winton, Jennifer,Han, Seungil,Pattavina, David
, p. 5989 - 5994,6 (2020/08/31)
Novel siderophore-linked monobactams with in vitro and in vivo anti-microbial activity against MDR Gram-negative pathogens are described.
MONOBACTAMS
-
Page/Page column 55, (2012/06/16)
The present invention is directed to a new class of monobactam derivatives and their use for treating bacterial infections.
